CoChat
Sign Up
Cited by 428

Lung cancer screening

Adams, Scott J, Stone, Emily, Baldwin, David R, Vliegenthart, Rozemarijn, Lee, Pyng, Fintelmann, Florian J·2023·The Lancet
DOI 10.1016/s0140-6736(22)01694-4
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)01694-4

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AI algorithms based on deep learning and convolutional neural networks have demonstrated high sensitivity up to 94.6% and specificity up to 93.6% for lung nodule detection, often matching or surpassing radiologist performance, especially for small nodules.

    “AI algorithms, especially those based on deep learning and convolutional neural networks, have demonstrated high sensitivity (up to 94.6%) and specificity (up to 93.6%) for lung nodule detection, often matching or surpassing radiologist performance, especially for small nodules [13,14].”

    From Artificial Intelligence in Oncologic Thoracic Surgery: Clinical Decision Support and Emerging Applications (2026) · cites this paper as [14]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 177

  1. Potter AL, Rosenstein AL, Kiang M V, et al. Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study. BMJ 2022; 376: e069008.
  2. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000; 92: 1308-16.
  3. Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996; 201: 798-802.
  4. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early lung cancer action project: overall design and findings from baseline screening. Lancet 1999; 354: 99-105.
  5. Yang W, Qian F, Teng J, et al. Community-based lung cancer screening with low-dose CT in China: results of the baseline screening. Lung Cancer 2018; 117: 20-26.
  6. Wille MMW, Dirksen A, Ashraf H, et al. Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med. 2016; 193: 542-51.
  7. Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol 2019; 30: 1162-69.
  8. Field JK, Vulkan D, Davies MPA, et al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Reg Health Eur 2021; 10: 100179.
  9. Becker N, Motsch E, Trotter A, et al. Lung cancer mortality reduction by LDCT screening-results from the randomized German LUSI trial. Int J Cancer 2020; 146: 1503-13.
  10. Doroudi M, Pinsky PF, Marcus PM. Lung cancer mortality in the Lung Screening Study feasibility trial. JNCI Cancer Spectr 2018; 2: 2-3.
  11. Paci E, Puliti D, Lopes Pegna A, et al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 2017; 72: 825-31.
  12. Infante M, Cavuto S, Lutman FR, et al. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med 2015; 191: 1166-75.
  13. Quaife SL, Ruparel M, Dickson JL, et al. Lung screen uptake trial (LSUT): randomized controlled clinical trial testing targeted invitation materials. Am J Respir Crit Care Med 2020; 201: 965-75.
  14. Blanchon T, Bréchot JM, Grenier PA, et al. Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest x-ray (CXR). Lung Cancer 2007; 58: 50-58.
  15. Horst C, Dickson JL, Tisi S, et al. Delivering low-dose CT screening for lung cancer: a pragmatic approach. Thorax 2020; 75: 831-32.
  16. Dickson JL, Bhamani A, Quaife SL, et al. The reporting of pulmonary nodule results by letter in a lung cancer screening setting. Lung Cancer 2022; 168: 46-49.
  17. Li N, Tan F, Chen W, et al. One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study. Lancet Respir Med 2022; 10: 378-391.
  18. International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355: 1763-71.
  19. Yang P. National Lung Cancer Screening Program in Taiwan: the TALENT study. J Thorac Oncol 2021; 16: S58.
  20. Lim KP, Marshall H, Tammemägi M, et al. Protocol and rationale for the International Lung Screening Trial. Ann Am Thorac Soc 2020; 17: 503-12.
  21. Tammemägi MC, Ruparel M, Tremblay A, et al. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol 2022; 23: 138-48.
  22. Lee J, Kim Y, Kim HY, et al. Feasibility of implementing a national lung cancer screening program: interim results from the Korean Lung Cancer Screening Project (K-LUCAS). Transl Lung Cancer Res 2021; 10: 723-36.
  23. Crosbie PA, Balata H, Evison M, et al. Implementing lung cancer screening: Baseline results from a community-based "Lung Health Check" pilot in deprived areas of Manchester. Thorax 2019; 74: 405-09.
  24. Tammemagi MC, Schmidt H, Martel S, et al. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. Lancet Oncol 2017; 18: 1523-31.
  25. Ghimire B, Maroni R, Vulkan D, et al. Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme. Lung Cancer 2019; 134: 66-71.
  26. Veronesi G, Maisonneuve P, Rampinelli C, et al. Computed tomography screening for lung cancer: results of ten years of annual screening and validation of cosmos prediction model. Lung Cancer 2013; 82: 426-30.
  27. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for lung cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 325: 962-70. 35 Croatia first EU country to introduce early lung cancer screening nationwide. Jan 14, 2020. https://hr.n1info.com/english/news/ a475221-croatia-first-eu-country-to-introduce-early-lung-cancer- screening-nationwide/ (accessed July 18, 2022).
  28. Herth FJF, Reinmuth N, Wormanns D, et al. Joint statement of the German Radiological Society and the German Respiratory Society on a quality-assured early detection program for lung cancer with low-dose CT. Pneumologie 2019; 73: 573-77.
  29. Rzyman W, Szurowska E, Adamek M. Implementation of lung cancer screening at the national level: Polish example. Transl Lung Cancer Res. 2019; 8: S95-105.
  30. Zhou Q, Fan Y, Wang Y, et al. China national lung cancer screening guideline with low-dose computed tomography (2018 version). Chinese J Lung Cancer 2018; 21: 67-75.
  31. Jazieh AR, AlGhamdi M, AlGhanem S, et al. Saudi lung cancer prevention and screening guidelines. Ann Thorac Med 2018; 13: 198-204.
  32. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol 2017; 18: e754-66.
  33. Canadian Task Force on Preventive Health Care. Recommendations on screening for lung cancer. CMAJ 2016; 188: 425-32.
  34. Jang SH, Sheen S, Kim HY, et al. The Korean guideline for lung cancer screening. J Korean Med Assoc 2015; 58: 291-301.
  35. Colson YL, Shepard J-AO, Lennes IT. New USPSTF guidelines for lung cancer screening: better but not enough. JAMA Surg 2021; 156: 513-14.
  36. Potter AL, Bajaj SS, Yang C-FJ. The 2021 USPSTF lung cancer screening guidelines: a new frontier. Lancet Respir Med 2021; 9: 689-91.
  37. Cancer Intervention and Surveillance Modeling Network (CISNET) Lung Cancer Working Group. Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: a collaborative modeling study for the U.S. Preventive Services Task Force. 2020. https://www.ncbi.nlm.nih.gov/books/NBK568586/pdf/ Bookshelf_NBK568586.pdf (accessed Nov 6, 2022).
  38. Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med 2013; 368: 728-736.
  39. Cassidy A, Myles JP, Van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008; 98: 270-76.
  40. Field JK, Duffy SW, Baldwin DR, et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax 2016; 71: 161-70.
  41. Tammemagi CM, Pinsky PF, Caporaso NE, et al. Lung cancer risk prediction: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst 2011; 103: 1058-68.
  42. Field JK, Vulkan D, Davies MPA, Duffy SW, Gabe R. Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation. Thorax 2021; 76: 161-68.
  43. Li K, Hüsing A, Sookthai D, et al. Selecting high-risk individuals for lung cancer screening: a prospective evaluation of existing risk models and eligibility criteria in the German EPIC cohort. Cancer Prev Res 2015; 8: 777-85.
  44. ten Haaf K, Jeon J, Tammemägi MC, et al. Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study. PLoS Med 2017; 14: e1002277.
  45. Robbins HA, Alcala K, Swerdlow AJ, et al. Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom. Br J Cancer 2021; 124: 2026-34.
  46. Katki HA, Kovalchik SA, Petito LC, et al. Implications of nine risk prediction models for selecting ever-smokers for computed tomography lung cancer screening. Ann Intern Med 2018; 169: 10-19.
  47. Park B, Lee J, Lee N, Kim Y, Hun Jang S. Risk-based prediction model for selecting eligible population for lung cancer screening among ever smokers in Korea. Transl Lung Cancer Res 2021; 10: 4390-402.
  48. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat Rev Cancer 2007; 7: 778-90.
  49. Lam S. Lung cancer screening in never-smokers. J Thorac Oncol 2019; 14: 336-37.
  50. Kang HR, Cho JY, Lee SH, et al. Role of low-dose computerized tomography in lung cancer screening among never-smokers. J Thorac Oncol 2019; 14: 436-44.
  51. Kakinuma R, Muramatsu Y, Asamura H, et al. Low-dose CT lung cancer screening in never-smokers and smokers: results of an eight- year observational study. Transl Lung Cancer Res 2020; 9: 10-22.
  52. National Lung Screening Trial Research Team. Results of initial low- dose computed tomographic screening for lung cancer. N Engl J Med 2013; 368: 1980-91.
  53. ten Haaf K, van der Aalst CM, de Koning HJ, Kaaks R, Tammemägi MC. Personalising lung cancer screening: an overview of risk-stratification opportunities and challenges. Int J Cancer 2021; 149: 250-63.
  54. Gao W, Wen CP, Wu A, Welch HG. Association of computed tomographic screening promotion with lung cancer overdiagnosis among Asian women. JAMA Intern Med 2022; 182: 283-90.
  55. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102: 605-13.
  56. Haddad DN, Sandler KL, Henderson LM, Rivera MP, Aldrich MC. Disparities in lung cancer screening: a review. Ann Am Thorac Soc 2020; 17: 399-405.
  57. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health 2019; 85: 1-16.
  58. Kligerman S, White C. Epidemiology of lung cancer in women: risk factors, survival, and screening. Am J Roentgenol 2011; 196: 287-95.
  59. Powell HA, Iyen-Omofoman B, Hubbard RB, Baldwin DR, Tata LJ. The association between smoking quantity and lung cancer in men and women. Chest 2013; 143: 123-29.
  60. Donin NM, Filson CP, Drakaki A, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992-2008. Cancer 2016; 122: 3075-86.
  61. Han SS, Rivera GA, Tammemägi MC, et al. Risk stratification for second primary lung cancer. J Clin Oncol 2017; 35: 2893-99.
  62. Barclay ME, Lyratzopoulos G, Walter FM, Jefferies S, Peake MD, Rintoul RC. Incidence of second and higher order smoking-related primary cancers following lung cancer: a population-based cohort study. Thorax 2019; 74: 466-72.
  63. Eberl M, Tanaka LF, Kraywinkel K, Klug SJ. Incidence of smoking- related second primary cancers after lung cancer in Germany: an analysis of nationwide cancer registry data. J Thorac Oncol 2022; 17: 388-98.
  64. Rivera MP, Henderson LM. Lung cancer screening and shared decision making in cancer survivors: the long and winding road. Transl Lung Cancer Res 2019; 8: 119-23.
  65. Schneider BJ, Ismaila N, Aerts J, et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol 2020; 38: 753-66.
  66. Ahn MI, Gleeson TG, Chan IH, et al. Perifissural nodules seen at CT screening for lung cancer. Radiology 2010; 254: 949-56.
  67. Sheard S, Moser J, Sayer C, Stefanidis K, Devaraj A, Vlahos I. Lung cancers associated with cystic airspaces: underrecognized features of early disease. Radiographics 2018; 38: 704-17.
  68. Fintelmann FJ, Brinkmann JK, Jeck WR, et al. Lung cancers associated with cystic airspaces: natural history, pathologic correlation, and mutational analysis. J Thorac Imaging 2017; 32: 176-88.
  69. Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol 2014; 15: 1332-41.
  70. Bankier AA, MacMahon H, Goo JM, Rubin GD, Schaefer-Prokop CM, Naidich DP. Recommendations for measuring pulmonary nodules at CT: a statement from the Fleischner Society. Radiology 2017; 285: 584-600.
  71. Devaraj A, Van Ginneken B, Nair A, Baldwin D. Use of volumetry for lung nodule management: theory and practice. Radiology 2017; 284: 630-44.
  72. Herder GJ, Van Tinteren H, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest 2005; 128: 2490-96.
  73. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med 2013; 369: 910-19.
  74. Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC lung cancer staging project: Proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 2015; 10: 990-03.
  75. Balata H, Ruparel M, O'Dowd E, et al. Analysis of the baseline performance of five UK lung cancer screening programmes. Lung Cancer 2021; 161: 136-40.
  76. Janssen K, Schertz K, Rubin N, Begnaud A. Incidental findings in a decentralized lung cancer screening program. Ann Am Thorac Soc 2019; 16: 1198-201.
  77. Morgan L, Choi H, Reid M, Khawaja A, Mazzone PJ. Frequency of incidental findings and subsequent evaluation in low-dose computed tomographic scans for lung cancer screening. Ann Am Thorac Soc 2017; 14: 1450-56.
  78. Adams SJ, Babyn PS, Danilkewich A. Toward a comprehensive management strategy for incidental findings in imaging. Can Fam Physician 2016; 62: 541-43.
  79. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008; 178: 738-44. 101
  80. De Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007; 132: 1932-38. 102
  81. Steiger D, Siddiqi MF, Yip R, et al. The importance of low-dose CT screening to identify emphysema in asymptomatic participants with and without a prior diagnosis of COPD. Clin Imaging 2021; 78: 136-41. 103
  82. Balata H, Harvey J, Barber PV, et al. Spirometry performed as part of the Manchester community-based lung cancer screening programme detects a high prevalence of airflow obstruction in individuals without a prior diagnosis of COPD. Thorax 2020; 75: 655-60. 104
  83. Mets O, Buckens C, Zanen P, et al. Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans. J Am Med Assoc 2011; 306: 1775-81. 105
  84. Mets OM, Schmidt M, Buckens CF, et al. Diagnosis of chronic obstructive pulmonary disease in lung cancer screening computed tomography scans: independent contribution of emphysema, air trapping and bronchial wall thickening. Respir Res 2013; 14: 1-8. 106
  85. Labaki WW, Xia M, Murray S, et al. Quantitative emphysema on low-dose CT imaging of the chest and risk of lung cancer and airflow obstruction: an analysis of the National Lung Screening Trial. Chest 2021; 159: 1812-0. 107
  86. Henschke CI, Yip R, Boffetta P, et al. CT screening for lung cancer: Importance of emphysema for never smokers and smokers. Lung Cancer 2015; 88: 42-47. 108
  87. Durawa A, Dziadziuszko K, Jelitto-Górska M, Szurowska E. Emphysema -the review of radiological presentation and its clinical impact in the LDCT screening era. Clin Imaging 2020; 64: 85-91. 109
  88. Pinsky PF, Lynch DA, Gierada DS. Incidental findings on low-dose CT scan lung cancer screenings and deaths from respiratory diseases. Chest 2022; 161: 1092-100. 110
  89. Sanchez-Salcedo P, Wilson DO, De-Torres JP, et al. Improving selection criteria for lung cancer screening: the potential role of emphysema. Am J Respir Crit Care Med 2015; 191: 924-31. 111
  90. Pinsky PF, Berg CD. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? J Med Screen 2012; 19: 154-56. 112
  91. Schreuder A, Jacobs C, Lessmann N, et al. Scan-based competing death risk model for reevaluating lung cancer computed tomography screening eligibility. Eur Respir J 2021; 59: 2101613. 113
  92. Behr CM, Koffijberg H, Degeling K, Vliegenthart R, IJzerman MJ. Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation. Eur Radiol 2022; 32: 3067-75. 114
  93. Ruparel M, Quaife SL, Dickson JL, et al. Evaluation of cardiovascular risk in a lung cancer screening cohort. Thorax 2019; 74: 1140-46. 115
  94. Balata H, Blandin Knight S, Barber P, et al. Targeted lung cancer screening selects individuals at high risk of cardiovascular disease. Lung Cancer 2018; 124: 148-53. 116
  95. Mascalchi M, Puliti D, Romei C, et al. Moderate-severe coronary calcification predicts long-term cardiovascular death in CT lung cancer screening: the ITALUNG trial. Eur J Radiol 2021; 145: 110040. 117
  96. Chiles C, Duan F, Gladish GW, et al. Association of coronary artery calcification and mortality in the National Lung Screening Trial: a comparison of three scoring methods. 2015; 276: 82-90. 118
  97. Suh YJ, Lee JW, Shin SY, Goo JM, Kim Y, Yong HS. Coronary artery calcium severity grading on non-ECG-gated low-dose chest computed tomography: a multiple-observer study in a nationwide lung cancer screening registry. Eur Radiol 2020; 30: 3684-91. 119
  98. Xie X, Zhao Y, De Bock GH, et al. Validation and prognosis of coronary artery calcium scoring in nontriggered thoracic computed tomography: systematic review and meta-analysis. Circ Cardiovasc Imaging 2013; 6: 514-21. 121
  99. Gendarme S, Goussault H, Assié JB, Taleb C, Chouaïd C, Landre T. Impact on all-cause and cardiovascular mortality rates of coronary artery calcifications detected during organized, low-dose, computed- tomography screening for lung cancer: systematic literature review and meta-analysis. Cancers 2021; 13: 1553. 122
  100. Williams MC, Abbas A, Tirr E, et al. Reporting incidental coronary, aortic valve and cardiac calcification on non-gated thoracic computed tomography, a consensus statement from the BSCI/ BSCCT and BSTI. Br J Radiol 2021; 94: 20200894. 123
  101. Vonder M, van der Aalst CM, Vliegenthart R, et al. Coronary artery calcium imaging in the ROBINSCA trial: rationale, design, and technical background. Acad Radiol 2018; 25: 118-28. 125
  102. Kathuria H, Detterbeck FC, Fathi JT, et al. Stakeholder research priorities for smoking cessation interventions within lung cancer screening programs an official American Thoracic Society research statement. Am J Respir Crit Care Med 2017; 196: 1202-12. 126
  103. Goffin JR, Flanagan WM, Miller AB, et al. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness. Lung Cancer 2016; 101: 98-103. 128
  104. Villanti AC, Jiang Y, Abrams DB, Pyenson BS. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS One 2013; 8: e71379. 129
  105. Balata H, Traverse-Healy L, Blandin-Knight S, et al. Attending community-based lung cancer screening influences smoking behaviour in deprived populations. Lung Cancer 2020; 139: 41-46. 130
  106. Ostroff JS, Buckshee N, Mancuso CA, Yankelevitz DF, Henschke CI. Smoking cessation following CT screening for early detection of lung cancer. Prev Med 2001; 33: 613-21. 131
  107. Moldovanu D, De Koning HJ, Van Der Aalst CM. Lung cancer screening and smoking cessation efforts. Transl Lung Cancer Res 2021; 10: 1099-09. 132
  108. Iaccarino JM, Duran C, Slatore CG, Wiener RS, Kathuria H. Combining smoking cessation interventions with LDCT lung cancer screening: a systematic review. Prev Med 2019; 121: 24-32. 134
  109. Murray RL, Brain K, Britton J, et al. Yorkshire Enhanced Stop Smoking (YESS) study: a protocol for a randomised controlled trial to evaluate the effect of adding a personalised smoking cessation intervention to a lung cancer screening programme. BMJ Open 2020; 10: 1-10. 135
  110. Joseph AM, Rothman AJ, Almirall D, et al. Lung cancer screening and smoking cessation clinical trials: SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med 2018; 197: 172-82. 136
  111. Taylor KL, Williams RM, Li T, et al. A randomized trial of telephone- based smoking cessation treatment in the lung cancer screening setting. J Natl Cancer Inst 2022; published online July 12. DOI:10.1093/jnci/djac127. 137 · DOI
  112. Peters JL, Snowsill TM, Griffin E, Robinson S, Hyde CJ. Variation in model-based economic evaluations of low-dose computed tomography screening for lung cancer: a methodological review. Value Health 2022; 25: 656-65. 138
  113. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med 2014; 371: 1793-802. 139
  114. Toumazis I, De Nijs K, Cao P, et al. Cost-effectiveness evaluation of the 2021 US Preventive Services Task Force recommendation for lung cancer screening. JAMA Oncol 2021; 7: 1833-42. 140
  115. Criss SD, Cao P, Bastani M, et al. Cost-effectiveness analysis of lung cancer screening in the United States. Ann Intern Med 2019; 171: 796-804. 141
  116. Du Y, Sidorenkov G, Heuvelmans MA, et al. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study. Eur J Cancer 2020; 135: 121-29. 142
  117. Hofer F, Kauczor HU, Stargardt T. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: a modelling approach. Lung Cancer 2018; 124: 189-98. 143
  118. Tomonaga Y, ten Haaf K, Frauenfelder T, et al. Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-a modelling study. Lung Cancer 2018; 121: 61-69. 144
  119. Hinde S, Crilly T, Balata H, et al. The cost-effectiveness of the Manchester 'lung health checks', a community-based lung cancer low-dose CT screening pilot. Lung Cancer 2018; 126: 119-24. 145
  120. Jaine R, Kvizhinadze G, Nair N, Blakely T. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand. Lung Cancer 2020; 144: 99-106. 146
  121. Yang SC, Lai WW, Lin CC, et al. Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan. Lung Cancer 2017; 108: 183-91. 147
  122. Black WC, Keeler EB, Soneji SS. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med 2015; 372: 388. 148
  123. Wilkinson AN, Lam S. Lung cancer screening primer: key information for primary care providers. Can Fam Physician 2021; 67: 817-22. 149
  124. Adams SJ, Mondal P, Penz E, Tyan C-C, Lim H, Babyn P. Development and cost analysis of a lung nodule management strategy combining artificial intelligence and Lung-RADS for baseline lung cancer screening. J Am Coll Radiol 2021; 18: 741-51. 150
  125. Tammemägi MC, Ten Haaf K, Toumazis I, et al. Development and validation of a multivariable lung cancer risk prediction model that includes low-dose computed tomography screening results: a secondary analysis of data from the National Lung Screening Trial. JAMA Netw Open 2019; 2: e190204. 151
  126. Schreuder A, Schaefer-Prokop CM, Scholten ET, Jacobs C, Prokop M, Van Ginneken B. Lung cancer risk to personalise annual and biennial follow-up computed tomography screening. Thorax 2018; 73: 626-33. 152
  127. Robbins HA, Berg CD, Cheung LC, Chaturvedi AK, Katki HA. Identification of candidates for longer lung cancer screening intervals following a negative low-dose computed tomography result. J Natl Cancer Inst 2019; 111: 996-99. 153
  128. Pastorino U, Boeri M, Sestini S, et al. Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial. Ann Oncol 2022; 33: 395-405. 154
  129. Hata A, Yanagawa M, Yoshida Y, et al. Combination of deep learning-based denoising and iterative reconstruction for ultra-low- dose CT of the chest: image quality and Lung-RADS evaluation. Am J Roentgenol 2020; 215: 1321-28. 155
  130. Setio AAA, Traverso A, de Bel T, et al. Validation, comparison, and combination of algorithms for automatic detection of pulmonary nodules in computed tomography images: the LUNA16 challenge. Med Image Anal 2017; 42: 1-13. 156
  131. Obuchowski NA, Bullen JA. Statistical considerations for testing an AI algorithm used for prescreening lung CT images. Contemp Clin Trials Commun 2019; 16: 100434. 157
  132. Ardila D, Kiraly AP, Bharadwaj S, et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nat Med 2019; 25: 954-61. 158
  133. Jiang B, Li N, Shi X, et al. Deep learning reconstruction shows better lung nodule detection for ultra-low-dose chest CT. Radiology 2022; 303: 202-12. 159
  134. Pehrson LM, Nielsen MB, Lauridsen CA. Automatic pulmonary nodule detection applying deep learning or machine learning algorithms to the LIDC-IDRI database: a systematic review. Diagnostics 2019; 9: 29. 160
  135. Cui X, Zheng S, Heuvelmans MA, et al. Performance of a deep learning-based lung nodule detection system as an alternative reader in a Chinese lung cancer screening program. Eur J Radiol 2022; 146: 110068. 161
  136. Martins Jarnalo CO, Linsen PVM, Blazís SP, van der Valk PHM, Dickerscheid DBM. Clinical evaluation of a deep-learning-based computer-aided detection system for the detection of pulmonary nodules in a large teaching hospital. Clin Radiol 2021; 76: 838-45. 162
  137. Venkadesh KV, Setio AAA, Schreuder A, et al. Deep learning for malignancy risk estimation of pulmonary nodules detected at low- dose screening CT. Radiology 2021; 300: 438-47. 163
  138. Baldwin DR, Gustafson J, Pickup L, et al. External validation of a convolutional neural network artificial intelligence tool to predict malignancy in pulmonary nodules. Thorax 2020; 75: 306-12. 164
  139. Li D, Vilmun BM, Carlsen JF, et al. The performance of deep learning algorithms on automatic pulmonary nodule detection and classification tested on different datasets that are not derived from LIDC-IDRI: a systematic review. Diagnostics 2019; 9: 207. 165
  140. Mikhael PG, Wohlwend J, Yala A, et al. Sybil: a validated deep learning model to predict future lung cancer risk from a single low- dose chest computed tomography. J Clin Oncol (in press). 167 Radboud University Medical Center. AI for Radiology -Products. 2022. https://grand-challenge.org/aiforradiology/ (accessed Nov 6, 2022). 168
  141. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012; 21: 308-315. 169
  142. Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 2014; 32: 768-73. 170
  143. Veronesi G, Bellomi M, Mulshine JL, et al. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer 2008; 61: 340-49. 171
  144. Sullivan FM, Mair FS, Anderson W, et al. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. Eur Respir J 2021; 57: 2000670. 173
  145. Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, Robertson JFR. Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer 2014; 83: 51-55. 174
  146. Maldonado SG, Johnson T, Motsch E, Delorme S, Kaaks R. Can autoantibody tests enhance lung cancer screening?-an evaluation of EarlyCDT®-Lung in context of the German Lung Cancer Screening Intervention Trial (LUSI). Transl Lung Cancer Res 2021; 10: 233-42. 175
  147. Guida F, Sun N, Bantis LE, et al. Assessment of lung cancer risk on the basis of a biomarker panel of circulating proteins. JAMA Oncol 2018; 4: e182078. 176
  148. Robbins HA, Alcala KM, Khodayari Moez E, et al. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) program. medRxiv 2022; 2022.03.21.22272544. https:// www.medrxiv.org/content/10.1101/2022.03.21.22272544v1.full.pdf. 177 · DOI
  149. Seijo LM, Peled N, Ajona D, et al. Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol 2019; 14: 343-57. 178
  150. Sears CR, Mazzone PJ. Biomarkers in lung cancer. Clin Chest Med 2020; 41: 115-27. 179
  151. Campanella A, De Summa S, Tommasi S. Exhaled breath condensate biomarkers for lung cancer. J Breath Res 2019; 13: 044002. 180
  152. Park J, Lee J, Kim Y. Public opinion on implementing the national lung cancer screening program in Korea. Transl Lung Cancer Res 2021; 10: 1355-67. 181
  153. Meerbeeck JP Van, Franck C. Lung cancer screening in Europe: where are we in 2021? Transl Lung Cancer Res 2021; 10: 2407-17. 182
  154. Darling GE, Tammemägi MC, Schmidt H, et al. Organized lung cancer screening pilot: informing a province-wide program in Ontario, Canada. Ann Thorac Surg 2021; 111: 1805-11. 183 UK National Screening Committee. Lung cancer. https://view- health-screening-recommendations.service.gov.uk/lung-cancer/ (accessed Nov 8, 2022). 184
  155. Henschke CI, Yankelevitz DF, Jirapatnakul A, et al. Implementation of low-dose CT screening in two different health care systems: Mount Sinai Healthcare System and Phoenix VA Health Care System. Transl Lung Cancer Res 2021; 10: 1064-82. 185
  156. Leishman NJ, Wiener RS, Fagerlin A, Hayward RA, Lowery J, Caverly TJ. Variation in eligible patients' agreeing to and receiving lung cancer screening: a cohort study. Am J Prev Med 2021; 60: 520-28. 186
  157. Núñez ER, Caverly TJ, Zhang S, et al. Adherence to follow-up testing recommendations in US veterans screened for lung cancer, 2015-2019. JAMA Netw Open 2021; 4: e2116233. 187
  158. Pham D, Bhandari S, Pinkston C, Oechsli M, Kloecker G. Lung cancer screening registry reveals low-dose CT screening remains heavily underutilized. Clin Lung Cancer. 2020; 21: e206-11. 188
  159. Zahnd WE, Eberth JM. Lung cancer screening utilization: a behavioral risk factor surveillance system analysis. Am J Prev Med 2019; 57: 250-55. 189
  160. Kee D, Wisnivesky J, Kale MS. Lung cancer screening uptake: analysis of BRFSS 2018. J Gen Intern Med 2021; 36: 2897-99. 190
  161. Baldwin DR, Brain K, Quaife S. Participation in lung cancer screening. Transl Lung Cancer Res 2021; 10: 1091-98. 191
  162. Simmons VN, Gray JE, Schabath MB, Wilson LE, Quinn GP. High-risk community and primary care providers knowledge about and barriers to low-dose computed topography lung cancer screening. Lung Cancer 2017; 106: 42-49. 192
  163. Kanodra NM, Pope C, Halbert CH, Silvestri GA, Rice LJ, Tanner NT. Primary care provider and patient perspectives on lung cancer screening: a qualitative study. Ann Am Thorac Soc 2016; 13: 1977-82. 193
  164. Carter-Harris L, Ceppa DKP, Hanna N, Rawl SM. Lung cancer screening: what do long-term smokers know and believe? Heal Expect 2017; 20: 59-68. 194
  165. Triplette M, Kross EK, Mann BA, et al. An assessment of primary care and pulmonary provider perspectives on lung cancer screening. Ann Am Thorac Soc 2018; 15: 69-75. 195
  166. Margariti C, Kordowicz M, Selman G, et al. Healthcare professionals' perspectives on lung cancer screening in the UK: a qualitative study. BJGP Open 2020; 4: 1-10. 196
  167. Shah M, Surapaneni PK, Sandhu K, et al. Assessment and efficacy of low-dose CT screening and primary care providers perspective on lung cancer screening: an institutional review. Cureus 2021; 13: 4-9. 197
  168. Wang GX, Baggett TP, Pandharipande PV, et al. Barriers to lung cancer screening engagement from the patient and provider perspective. Radiology 2019; 290: 278-87. 198
  169. Mazzone PJ, Silvestri GA, Souter LH, et al. Screening for lung cancer: CHEST guideline and expert panel report. Chest 2021; 160: e427-94. 199
  170. Melzer AC, Wilt TJ. Expanded access to lung cancer screening- implementing wisely to optimize health. JAMA Netw Open 2021; 4: e210275. 200
  171. Narayan AK, Chowdhry DN, Fintelmann FJ, Little BP, Shepard JAO, Flores EJ. Racial and ethnic disparities in lung cancer screening eligibility. Radiology 2021; 301: 712-20. 201
  172. Sahar L, Douangchai Wills VL, Liu KK, et al. Geographic access to lung cancer screening among eligible adults living in rural and urban environments in the United States. Cancer 2022; 128: 1584-94. 202
  173. Page BJ, Bowman R V., Yang IA, Fong KM. A survey of lung cancer in rural and remote Aboriginal and Torres Strait Islander communities in Queensland: health views that impact on early diagnosis and treatment. Intern Med J 2016; 46: 171-76. 203
  174. Balata H, Tonge J, Barber P V, et al. Attendees of Manchester's Lung Health Check pilot express a preference for community-based lung cancer screening. Thorax 2019; 74: 1176-78. 204
  175. Lee C. Screening for lung cancer: effective recruitment methods. Am J Roentgenol 2018; 210: 514-17. 205 The Lancet Respiratory Medicine. Feasibility of lung cancer screening in resource-poor areas. Lancet Respir Med 2022; 10: 313. 206
  176. Triphuridet N, Henschke C. Landscape on CT screening for lung cancer in Asia. Lung Cancer Targets Ther 2019; 10: 107-24. 207
  177. Shankar A, Saini D, Dubey A, et al. Feasibility of lung cancer screening in developing countries: challenges, opportunities and way forward. Transl Lung Cancer Res 2019; 8: S106-121.

Cited by

Sorted by citations

Authors
Adams, S. J., Stone, E., Baldwin, D. R., Vliegenthart, R., Lee, P., & Fintelmann, F. J.
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-02
Volume
401
Issue
10374
Pages
390-408
ISSN
0140-6736
DOI
10.1016/s0140-6736(22)01694-4
Cited by
428
References
7
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review